Petersen_2024_Curr.Drug.Metab__

Reference

Title : Drug-Drug Interaction Potential of Remimazolam Mediated by CYP 450, Transporters, and Protein Binding - Petersen_2024_Curr.Drug.Metab__
Author(s) : Petersen KU , Schmalix W , Pesic M , Stohr T
Ref : Curr Drug Metab , : , 2024
Abstract :

BACKGROUND: The ultra-short-acting benzodiazepine, remimazolam, is a new treatment modality for procedural sedation and general anesthesia. Its activity is terminated by carboxylesterase 1 (CES1). OBJECTIVE: The objective of this study was to determine the drug-drug interaction (DDI) potential of remi-mazolam through mechanisms unrelated to its metabolizing enzyme, CES1. METHODS: Conventional in vitro co-exposure experiments were conducted to study possible interactions of remimazolam and its primary metabolite, CNS7054, mediated by competitive binding to plasma protein or competition for reactions with cytochrome P450 isoforms or drug transporters. RESULTS: No relevant interactions of remimazolam or its metabolite with cytochrome P450 (CYP) isoforms at clinically relevant concentrations were identified. Likewise, standard experiments revealed no clinically relevant interactions with drug transporters and plasma proteins. CONCLUSION: The present data and analyses suggest a very low potential of remimazolam for pharmacoki-netic DDIs mediated by CYP isoforms, drug transporters, and protein binding.

PubMedSearch : Petersen_2024_Curr.Drug.Metab__
PubMedID: 38818914

Related information

Citations formats

Petersen KU, Schmalix W, Pesic M, Stohr T (2024)
Drug-Drug Interaction Potential of Remimazolam Mediated by CYP 450, Transporters, and Protein Binding
Curr Drug Metab :

Petersen KU, Schmalix W, Pesic M, Stohr T (2024)
Curr Drug Metab :